<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Camilleri, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) of a variety of serum proteins, many of which circulate as constituents of plasma [<a href="#rid1">1</a>]. The subunit proteins forming amyloid deposits are derived from soluble precursors which have undergone conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration. Deposition into tissues results in organ dysfunction. These fibrils can be identified on biopsy specimens both by their characteristic appearance on electron microscopy and by their ability to bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence). These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition.</p><p>This topic will review the clinical manifestations, diagnosis, and management of gastrointestinal amyloidosis. A general overview of the genetics, pathogenesis, clinical manifestations, diagnosis, and treatment of the different amyloid disorders is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/5590.html" rel="external">"Genetic factors in the amyloid diseases"</a> and  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">"Renal amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/1983.html" rel="external">"Dialysis-related amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/5616.html" rel="external">"Musculoskeletal manifestations of amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H628577004"><span class="h1">TYPES OF AMYLOID</span><span class="headingEndMark"> — </span>There are several major forms of amyloidosis. Amyloidosis is classified based on the fibril precursor protein. Nomenclature for amyloid subunit proteins includes the letter "A," followed by the abbreviation of the name of the precursor protein [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Types of amyloidosis'</a>.)</p><p>The most common causes of systemic amyloid deposition are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>AL amyloid (also called immunoglobulin light chain amyloidosis), caused by a plasma cell dyscrasia, is due to deposition of protein derived from immunoglobulin light chain fragments. AL amyloidosis is the most prevalent type of amyloidosis [<a href="#rid3">3</a>]. The prognosis of patients with AL amyloidosis and gastrointestinal (GI) involvement appears to be worse than in patients without GI involvement; in addition, those with GI involvement may have more other organs involved and more advanced disease than those without organ involvement [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AA amyloidosis is a potential complication of chronic diseases in which there is ongoing or recurring inflammation that results in the production of serum amyloid A protein, a normal acute phase reactant protein sometimes referred to as SAA, which can form amyloid deposits (eg, chronic degenerative arthropathies, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, inflammatory bowel disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other major forms of amyloid seen clinically include dialysis-related amyloidosis (in which the non-glycosylated protein, beta 2-microglobulin, is deposited in organs), age-related (also called senile amyloidosis) systemic amyloidosis, and organ-specific amyloid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A rare form of hereditary amyloidosis is hereditary transthyretin amyloidosis that results from a single amino acid substitution in TTR gene, was previously called transthyretin familial amyloid polyneuropathy (TTR-FAP) or familial amyloid cardiomyopathy (TTR-FAC). Although, there are 120 amyloidogenic TTR mutations identified. The most common mutations in the United States are Val122Ile, Thr60Ala, and Val30Met [<a href="#rid5">5</a>]. The phenotype is variable (as in other types of amyloidosis), although polyneuropathy or cardiomyopathy may be more likely with certain TTR mutations. The following table summarizes the commonest forms of systemic amyloidosis, with their associated parent protein, distribution, and organs involved  (<a class="graphic graphic_table graphicRef129705" href="/z/d/graphic/129705.html" rel="external">table 1</a>) [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H1467472912"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Amyloidosis of the gastrointestinal tract may be limited to the gut or part of systemic involvement. In a retrospective review of 2334 patients with amyloidosis, 76 patients (3 percent) had biopsy-proven amyloid involvement of the gastrointestinal tract of which approximately 80 percent had systemic amyloidosis and 20 percent had amyloidosis of the gastrointestinal tract without evidence of an associated plasma cell dyscrasia or other organ involvement [<a href="#rid6">6</a>].</p><p>The distribution of clinically apparent gastrointestinal involvement varies with the type of amyloidosis [<a href="#rid7">7</a>]. Gastrointestinal disease is present in as many as 60 percent of patients with AA amyloidosis [<a href="#rid8">8</a>]. In contrast, gastrointestinal tract involvement appears to be less common in AL amyloidosis, with biopsy diagnosed disease and clinically apparent disease occurring in 8 and 1 percent of patients, respectively [<a href="#rid9">9</a>]. In autopsy series, 56 to 95 percent of patients with amyloidosis have hepatic involvement [<a href="#rid10">10,11</a>]. Hepatic amyloid has been reported in up to 90 percent of patients with AL amyloid and 60 percent of patients with AA amyloid. </p><p>The prevalence of dialysis-related amyloidosis has not been well studied but clinically apparent disease does not appear to be common [<a href="#rid12">12</a>]. Senile amyloidosis is found in 10 to 36 percent of patients over 80 years old and mainly involves the heart, but can also be seen throughout the gastrointestinal tract. Amyloid has been reported in subserosal veins of 41 to 44 percent of older adult patients, mainly in the large and small bowel [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Gastrointestinal disease in amyloidosis results from either mucosal infiltration or neuromuscular infiltration. In addition, an extrinsic autonomic neuropathy may also affect gut function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal infiltration</strong> – The most common sites of mucosal infiltration are the second part of the duodenum (100 percent), the stomach and colorectum (&gt;90 percent), and the esophagus (approximately 70 percent)  (<a class="graphic graphic_picture graphicRef81395 graphicRef73928 graphicRef58003" href="/z/d/graphic/81395.html" rel="external">picture 1A-C</a>) [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In AL amyloidosis, amyloid deposition in the muscularis mucosae, submucosa, and muscularis propria leads to polypoid protrusions and thickening of the valvulae conniventes. As a result, AL amyloidosis usually presents with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In AA amyloidosis, granular amyloid deposition occurs mainly in the mucosa, resulting in the fine granular appearance, mucosal friability, and erosions. As a result, AA amyloidosis presents with diarrhea and malabsorption [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with dialysis-related amyloid, the development of gastrointestinal amyloidosis is associated with the length of time on dialysis [<a href="#rid12">12</a>]. Vascular deposition can range from subtle hyalinization of the vascular intima and media within submucosal vessels to significant thickening of the vessel wall with resultant mucosal ischemia. Interstitial deposits are usually localized to the mucosa, submucosa, and muscularis propria but can range from immunoreactive beta<sub>2-</sub>microglobulin amyloid without mural expansion to macroscopic nodular deposits (amyloid tumors) within the muscularis propria. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular</strong> <strong>infiltration </strong>– Neuromuscular infiltration has been reported in patients with AL, AA, and dialysis-related amyloid and usually induces stasis syndromes. Neuromuscular infiltration initially affects the intrinsic nervous system and results in a neuropathic process that is characterized by normal amplitude but uncoordinated contractions [<a href="#rid16">16,17</a>]. Tissue wall infiltration results in a myopathic process with low amplitude contractions that are typically associated with significantly prolonged transit  (<a class="graphic graphic_waveform graphicRef62577" href="/z/d/graphic/62577.html" rel="external">waveform 1</a>) [<a href="#rid18">18</a>]. The preferential site of amyloid infiltration varies by the type of amyloidosis [<a href="#rid19">19,20</a>]. In one study that evaluated 16 patients with amyloidosis and intestinal pseudo-obstruction (13 with AA, 2 with AL, and 1 with dialysis-related amyloidosis), extensive infiltration and replacement of the muscularis propria by amyloid deposits throughout the gastrointestinal tract, especially the small intestine, were found in AL and dialysis-related amyloidosis cases. In contrast, in patients with AA amyloidosis, there was amyloid infiltration in the myenteric plexus without appreciable muscle infiltration. </p><p></p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H21931579"><span class="h2">Clinical presentation</span></p><p class="headingAnchor" id="H6"><span class="h3">Gastrointestinal tract amyloidosis</span><span class="headingEndMark"> — </span>Patients with symptomatic gastrointestinal amyloidosis usually present with one of four syndromes [<a href="#rid9">9,21-26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal bleeding</strong> – Bleeding is the presenting symptom in 25 to 45 percent of patients with gastrointestinal tract amyloidosis [<a href="#rid27">27,28</a>]. Bleeding may be due to ischemia or infarction, vascular friability, or mucosal lesions (ulcers, nodularity or polypoid lesions, erosions, submucosal hematomas, and small mucosal hemorrhages) [<a href="#rid6">6,29-31</a>]. Occult bleeding is the most commonly reported gastrointestinal (GI) presentation of B2M-amyloidosis [<a href="#rid32">32</a>]. (See <a class="local">'Types of amyloid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malabsorption </strong>– Patients with amyloidosis may develop malabsorption due to mucosal infiltration, pancreatic insufficiency or bacterial overgrowth and present with weight loss (median 13.6 kg in one series), diarrhea, or steatorrhea [<a href="#rid33">33,34</a>]. Less common features included anorexia, dizziness, hypotension, or orthostatic changes in blood pressure. (See  <a class="medical medical_review" href="/z/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein-losing gastroenteropathy </strong>– Patients with protein-losing gastroenteropathy usually present with diarrhea, edema, ascites, pleural or pericardial effusion and have laboratory evidence of hypoalbuminemia [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic gastrointestinal dysmotility </strong>– Less often, patients may present with constipation, or nausea, vomiting, abdominal pain, bloating, or chronic intestinal pseudo-obstruction [<a href="#rid16">16,19</a>]. Dysmotility can also result in rapid intestinal transit and cause diarrhea [<a href="#rid36">36</a>]. In hereditary transthyretin amyloidosis, 24-hour, small, intestinal motility studies show more daytime phase III migrating motor complexes than patient controls (which may be a feature of vagal denervation) and a lower amplitude of small intestinal contractions; together these features would be consistent with a combined neuromyopathic disorder [<a href="#rid37">37</a>]. (See <a class="local">'Types of amyloid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other rare symptoms of amyloidosis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cholangitis due amyloid deposition at the ampulla of Vater [<a href="#rid38">38</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>Bowel obstruction due to encapsulating peritonitis or extraluminal amyloidoma [<a href="#rid39">39,40</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>Bowel perforation in light chain amyloidosis, which may occur after the initiation of anti-AL therapy (eg, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> or thalidomide-based therapy) [<a href="#rid41">41</a>]. </p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal involvement due to amyloid deposition in nerves and resulting in dysphagia, heartburn, dysmotility (up to aperistalsis that may mimic achalasia), dilatation, and low lower esophageal sphincter (LES) pressure.</p><p class="bulletIndent2"><span class="glyph">•</span>Pneumatosis intestinalis [<a href="#rid42">42</a>].</p><p></p><p>While patients with AA amyloidosis usually present with diarrhea and malabsorption, patients with AL amyloidosis usually present with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction [<a href="#rid15">15</a>].</p><p>When there is involvement of the GI tract in senile systemic amyloidosis, it is usually discovered incidentally on histological examination within subserosal veins of the large and small bowel. It is present in about 40 percent of those &gt;80 years of age [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3913865174"><span class="h2">Amyloidosis secondary to inflammatory bowel disease</span><span class="headingEndMark"> — </span>AA amyloidosis is a rare complication of inflammatory bowel disease (~1 in 200 cases), and is 10 to 15 times more likely in Crohn disease than ulcerative colitis, presumably because of the greater systemic inflammation. Typically, AA amyloidosis occurs in association with male sex, fistulizing behavior, extraintestinal manifestations, perianal disease, and ileocolic anatomical location. Renal disease is the most common organ involved in AA amyloidosis associated with inflammatory bowel disease [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H8"><span class="h3">Hepatic amyloidosis</span><span class="headingEndMark"> — </span>Clinical manifestations of hepatic amyloid deposition are usually mild with hepatomegaly and elevated alkaline phosphatase being the most frequent findings [<a href="#rid44">44</a>]. Patients with hepatic amyloidosis often have concurrent symptoms of fatigue, weight loss, and anorexia due to systemic amyloidosis.</p><p>Hepatomegaly is present in 57 to 83 percent of patients with hepatic amyloidosis and does not correlate with the amount of amyloid deposition [<a href="#rid10">10,45</a>]. While patients may have associated ascites, this is more likely due to concurrent heart failure or hypoalbuminemia. Chronic liver disease and portal hypertension are rare. The most frequently abnormal test of hepatic function is an elevated serum alkaline phosphatase level. In one study that included 98 patients with hepatic amyloidosis, an elevated alkaline phosphatase was noted in 86 percent of patients, of which 61 percent had values of 500 int. units/L or more [<a href="#rid46">46</a>]. The serum aspartate aminotransferase (AST) was more than twice the upper limit of normal in 37 percent of patients.</p><p>Hepatic involvement can be seen in up to 90 percent of patients with AL amyloid and 60 percent of patients with AA amyloidosis [<a href="#rid10">10,11,47</a>]. Clinical features of hepatic involvement in AA amyloidosis are similar to those seen in AL amyloidosis. Although histologic differences between AL and AA amyloidosis have been described, there is considerable overlap making the significance of these observations unclear [<a href="#rid47">47-49</a>]. </p><p>Although some case reports have suggested that patients with hepatic amyloidosis have an increased risk of bleeding and/or hepatic rupture following the biopsy, this has not been consistently demonstrated [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/3587.html" rel="external">"Approach to liver biopsy"</a>.) Rarely, ascites may result from peritoneal amyloidosis [<a href="#rid50">50</a>]. </p><p class="headingAnchor" id="H438020436"><span class="h2">Imaging findings</span><span class="headingEndMark"> — </span>Radiologic and endoscopic findings of gastrointestinal amyloidosis are nonspecific [<a href="#rid51">51</a>] and the diagnosis typically requires biopsy and special stains to identify the amyloid infiltration and the specific nature of the amyloid protein infiltration [<a href="#rid52">52</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal tract amyloidosis </strong>– On small bowel follow-through and cross sectional imaging with computed tomographic (CT) scan or magnetic resonance imaging (MRI) in patients with AA amyloid, the mucosa may have a coarse mucosal pattern with innumerable fine granular elevations due to expansion of the lamina propria by amyloid deposits [<a href="#rid53">53</a>]. In patients with AL amyloid, findings include polypoid protrusions or masses that may mimic cancer, thickening of the folds, luminal narrowing, loss of haustrations, thickened mucosal folds, mucosal nodularity, and ulceration. Dilatation of the small bowel or colon may be seen in patients with neuromuscular amyloid infiltration  (<a class="graphic graphic_diagnosticimage graphicRef77965" href="/z/d/graphic/77965.html" rel="external">image 1</a>). Rarely mesenteric thickening or adenopathy may be seen on CT scan [<a href="#rid53">53</a>]. The appearance of primary amyloidosis in the intestine may mimic Crohn disease [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic amyloidosis </strong>– Ultrasonographic findings of hepatic amyloidosis include heterogeneous echogenicity [<a href="#rid51">51</a>]. On CT scan, diffuse or focal regions of decreased parenchymal attenuation with or without extensive calcification may be seen. MRI demonstrates significantly increased signal intensity on T1-weighted images of the liver without significantly altered signal intensity on T2-weighted images; the reason for high signal intensity on T1 is unclear.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Gastrointestinal amyloidosis should be suspected in patients with diarrhea, weight loss, or gastrointestinal bleeding and disorders known to be associated with amyloidosis (eg, plasma cell dyscrasia, chronic inflammatory disease, and chronic renal failure on maintenance dialysis). Amyloidosis should also be suspected when there is involvement of other organs characteristic of systemic amyloid deposition (eg, proteinuria, hepatomegaly and elevated alkaline phosphatase, restrictive cardiomyopathy, neuropathy, unexplained edema, carpal tunnel syndrome, unexplained facial or neck purpura, or macroglossia). The diagnosis of gastrointestinal amyloid requires a tissue biopsy with positive staining of amyloid by Congo red or the presence of amyloid fibrils on electron microscopy. (See  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Clinical manifestations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue biopsy</strong> – Based on the gastrointestinal symptoms, we perform a colonoscopy and/or an upper endoscopy to obtain rectal or duodenal mucosal biopsies in patients with suspected amyloidosis and to exclude other etiologies. In patients with unexplained hepatomegaly and elevated alkaline phosphatase, a liver biopsy serves to establish the diagnosis of hepatic amyloid and rule out other infiltrative liver diseases. (See <a class="local">'Differential diagnosis'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endoscopy</strong> – The endoscopic appearance of amyloidosis is not specific. The gastrointestinal tract mucosa may have a fine granular appearance, polypoid protrusions, erosions, ulcerations, friability, and thickening of the wall [<a href="#rid14">14,55</a>]. Rarely, patients have tumor-forming deposits of amyloid, called amyloidomas [<a href="#rid56">56-58</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histology</strong> – On hematoxylin and eosin stained biopsy sections, amyloid appears as a pink, amorphous, waxy substance with a characteristic 'cracking' artifact  (<a class="graphic graphic_picture graphicRef81395 graphicRef73928 graphicRef58003" href="/z/d/graphic/81395.html" rel="external">picture 1A-C</a>). In the gastrointestinal tract, amyloid deposits may be seen in the mucosa and submucosa and are best identified in the wall of blood vessels. In patients with hepatic amyloid, deposits are usually seen periportally in the space of Disse but the deposits are occasionally centrilobular. Atrophy of hepatocytes may be seen due to compression by amyloid fibrils [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent2">The presence of amyloid fibrils can be confirmed by their characteristic appearance on electron microscopy and by their ability to bind Congo red (leading to green birefringence under polarized light) or thioflavine-T (producing an intense yellow-green fluorescence) [<a href="#rid2">2</a>]. It is important to note that biopsy sections that are very thin (ie, 6 microns or less) may not stain appropriately with Congo red despite the presence of amyloid fibrils on electron microscopy. AL, Aβ2M, and ATTR amyloids are likely to deposit submucosally, while AA amyloid is easily deposited in the superficial layer of the mucous membrane [<a href="#rid60">60</a>]. Among 521 patients with biopsies from the gastrointestinal tract, the type of amyloid deposition was ALλ amyloid in 286 (52.8 percent), ATTR in 88 (16.2 percent), ALκ in 74 (13.7 percent), AA in 58 (10.7 percent), and apolipoprotein A- amyloid in four (0.7 percent) patients [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Determining the type of amyloid and underlying etiology</strong> – Once the histologic diagnosis of amyloidosis is made, it is important to determine the type of amyloid and the underlying cause [<a href="#rid61">61</a>]. This evaluation is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Determining the type of amyloid'</a> and  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Histopathology and protein analysis'</a>.) </p><p></p><p class="headingAnchor" id="H628576679"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of gastrointestinal amyloidosis varies based on the clinical presentation. Other causes of diarrhea with mucosal erosions include inflammatory bowel disease (ulcerative colitis and Crohn disease), radiation colitis, gastrointestinal malignancies, and medication-induced enteropathy. Gastrointestinal tract amyloidosis can be differentiated from these by a history which may be suggestive of the underlying cause and by histology. The differential diagnosis for chronic diarrhea and the evaluation of diarrhea are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p>The differential diagnosis of hepatomegaly and elevated alkaline phosphatase includes other infiltrative disorders of the liver including sarcoidosis, tuberculosis, malignancy, and glycogen storage diseases. These can be distinguished from hepatic amyloidosis by liver biopsy. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Therapy is directed at the gastrointestinal manifestations and at the underlying cause of amyloidosis.</p><p class="headingAnchor" id="H7051724"><span class="h2">Symptomatic treatment</span><span class="headingEndMark"> — </span>In patients with nausea and vomiting or abdominal pain, which is often due to amyloid-related dysmotility, management consists of dietary modification, hydration, and pharmacologic therapy with prokinetics (eg, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, and, where approved, <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>) and anti-emetics (eg, <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">promethazine</a>, <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">dimenhydrinate</a>, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>). Small meals consisting of liquid or homogenized foods are better tolerated than solids. Hypercaloric liquid formulations should be used in patients with low caloric intake. <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> may be necessary for patients with severe dysmotility who have failed enteral nutrition together with prokinetics and antiemetic therapy [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">"Treatment of gastroparesis", section on 'Prokinetics'</a> and  <a class="medical medical_review" href="/z/d/html/132410.html" rel="external">"Chronic intestinal pseudo-obstruction: Management", section on 'Symptomatic management'</a>.)</p><p>In patients with diarrhea and bloating and demonstrated small intestinal bacterial overgrowth, we suggest empiric treatment with antibiotics for small intestinal bacterial overgrowth (eg, quinolones, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>). In case reports, patients with severe diarrhea and hypoalbuminemia due to a protein-losing enteropathy have responded to glucocorticoids and <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management", section on 'Antibiotic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Management'</a>.)</p><p>The initial management of patients with gastrointestinal bleeding includes triage to the appropriate setting for management (outpatient, inpatient, intensive care unit), general supportive measures (eg, oxygen, establishment of adequate intravenous access), appropriate fluid and blood product resuscitation, and management of coagulopathies, anticoagulants, and antiplatelet agents. In many cases, the bleeding can be controlled with therapies applied at the time of endoscopy or angiography. The management of gastrointestinal bleeding is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H7051730"><span class="h2">Treatment of the underlying disorder</span><span class="headingEndMark"> — </span>Treatment of the underlying disease has been associated with regression of gastrointestinal amyloid  (<a class="graphic graphic_table graphicRef87769" href="/z/d/graphic/87769.html" rel="external">table 2</a>) [<a href="#rid64">64-68</a>]. As examples, therapy is aimed at the underlying infectious or inflammatory disorder in secondary AA amyloidosis (eg, anti-TNF therapy in Crohn disease), at the underlying plasma cell dyscrasia in AL amyloidosis, and at either altering the mode of dialysis or considering renal transplantation in patients with dialysis-related amyloidosis. The management of underlying cause of amyloidosis is discussed in detail, separately [<a href="#rid69">69-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">"Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p class="headingAnchor" id="H628577010"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Although the gastrointestinal complications can result in significant morbidity, they are not usually the cause of death, which is most often due to renal failure, restrictive cardiomyopathy, or ischemic heart disease. However, the presence of hepatic manifestations has a poor prognosis as it likely reflects relatively severe systemic disease [<a href="#rid44">44,77</a>]. In one series of 98 patients with hepatic amyloidosis, the median survival in patients with hepatic amyloidosis was nine months [<a href="#rid46">46</a>]. Independent predictors of shortened survival included heart failure, a total bilirubin &gt;2 mg/dL, and a platelet count &gt;500,000/microL. Novel agents (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a>) and autologous stem cell transplantation, used for eliminating the underlying plasma cell clone, have improved the outcome for low- and intermediate-risk patients, but the prognosis for high-risk patients is still grave [<a href="#rid78">78</a>]. There is an ongoing search for novel treatment approaches to AL amyloidosis. Early diagnosis is of paramount importance for effective treatment and prognosis due to the progressive nature of this disease.</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis is a generic term that refers to the extracellular tissue deposition of a variety of serum proteins, many of which circulate as constituents of plasma. The most common causes of systemic amyloid deposition are AL amyloid caused by a plasma cell dyscrasia and AA amyloidosis due to ongoing or recurring inflammation from chronic disease. Other major forms of amyloid seen clinically include dialysis-related amyloidosis, heritable amyloidosis, age-related systemic amyloidosis, and organ-specific amyloidosis. (See <a class="local">'Introduction'</a> above and <a class="local">'Types of amyloid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal disease in amyloidosis results from either mucosal or neuromuscular infiltration. In addition, an extrinsic autonomic neuropathy may also affect gut function. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with symptomatic gastrointestinal amyloidosis usually present with one of four syndromes: gastrointestinal bleeding, malabsorption, protein-losing gastroenteropathy, and, less often, gastrointestinal dysmotility. While patients with AA amyloidosis usually present with diarrhea and weight loss, patients with AL amyloidosis usually present with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction.</p><p></p><p class="bulletIndent1">Clinical manifestations of hepatic amyloid deposition are usually mild with hepatomegaly and elevated alkaline phosphatase being the most frequent findings. However, patients usually have weight loss, fatigue, and anorexia due to systemic involvement. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal amyloidosis should be suspected in patients with diarrhea, weight loss, or gastrointestinal bleeding and disorders known to be associated with amyloidosis (eg, plasma cell dyscrasia, chronic inflammatory disease, and chronic renal failure on maintenance dialysis). Amyloidosis should also be suspected when there is involvement of other organs characteristic of systemic amyloid deposition (eg, proteinuria, hepatomegaly and elevated alkaline phosphatase, restrictive cardiomyopathy, neuropathy, unexplained edema, carpal tunnel syndrome, unexplained facial or neck purpura, or macroglossia). The diagnosis of gastrointestinal amyloid requires a tissue biopsy with positive staining of amyloid by Congo red or the presence of amyloid fibrils on electron microscopy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the gastrointestinal complications can result in significant morbidity, they are not usually the cause of death, which is most often due to renal failure, restrictive cardiomyopathy, or ischemic heart disease. However, the presence of hepatic manifestations has a poor prognosis as it likely reflects relatively severe systemic disease. Therapy is directed at the gastrointestinal manifestations and at the underlying cause of amyloidosis. Early diagnosis is of paramount importance for effective treatment and prognosis due to the progressive nature of this disease. (See <a class="local">'Management'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nordling E, Abraham-Nordling M. Colonic amyloidosis, computational analysis of the major amyloidogenic species, Serum Amyloid A. Comput Biol Chem 2012; 39:29.</a></li><li><a class="nounderline abstract_t">Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980; 302:1283.</a></li><li><a class="nounderline abstract_t">Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel) 2016; 2:10.</a></li><li><a class="nounderline abstract_t">Lim AY, Lee JH, Jung KS, et al. Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. Korean J Intern Med 2015; 30:496.</a></li><li><a class="nounderline abstract_t">Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care 2017; 23:S107.</a></li><li><a class="nounderline abstract_t">Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013; 98:141.</a></li><li><a class="nounderline abstract_t">Freudenthaler S, Hegenbart U, Schönland S, et al. Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients. Virchows Arch 2016; 468:569.</a></li><li><a class="nounderline abstract_t">Okuda Y, Takasugi K, Oyama T, et al. [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases]. Ryumachi 1994; 34:939.</a></li><li><a class="nounderline abstract_t">Menke DM, Kyle RA, Fleming CR, et al. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993; 68:763.</a></li><li><a class="nounderline abstract_t">LEVINE RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med 1962; 33:349.</a></li><li><a class="nounderline abstract_t">Iwata T, Hoshii Y, Kawano H, et al. Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Hum Pathol 1995; 26:1148.</a></li><li><a class="nounderline abstract_t">Jimenez RE, Price DA, Pinkus GS, et al. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 1998; 22:729.</a></li><li><a class="nounderline abstract_t">Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011; 24:1533.</a></li><li><a class="nounderline abstract_t">Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc 1990; 36:10.</a></li><li><a class="nounderline abstract_t">Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc 1994; 40:45.</a></li><li><a class="nounderline abstract_t">Battle WM, Rubin MR, Cohen S, Snape WJ Jr. Gastrointestinal-motility dysfunction in amyloidosis. N Engl J Med 1979; 301:24.</a></li><li><a class="nounderline abstract_t">Camilleri M, Malagelada JR, Stanghellini V, et al. Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology 1985; 88:1852.</a></li><li class="breakAll">Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders, Thieme Medical Publishers, New York 1986.</li><li><a class="nounderline abstract_t">Tada S, Iida M, Yao T, et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34:1412.</a></li><li><a class="nounderline abstract_t">Tada S, Iida M, Yao T, et al. Gastrointestinal amyloidosis: radiologic features by chemical types. Radiology 1994; 190:37.</a></li><li><a class="nounderline abstract_t">Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103:776.</a></li><li><a class="nounderline abstract_t">Petre S, Shah IA, Gilani N. Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy. Aliment Pharmacol Ther 2008; 27:1006.</a></li><li><a class="nounderline abstract_t">Reddy MB, Poppers DM, Uram-Tuculescu C. Recurrent obscure gastrointestinal bleeding in a patient with gastric amyloid. Clin Gastroenterol Hepatol 2009; 7:e1.</a></li><li><a class="nounderline abstract_t">Kim SH, Kang EJ, Park JW, et al. Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding. Cardiovasc Intervent Radiol 2009; 32:577.</a></li><li><a class="nounderline abstract_t">Baldewijns M, Ectors N, Verbeeck G, et al. Intermittent subobstruction and cholestasis as complications of duodenal amyloid tumours. Gastroenterol Clin Biol 1995; 19:218.</a></li><li><a class="nounderline abstract_t">Hemmer PR, Topazian MD, Gertz MA, Abraham SC. Globular amyloid deposits isolated to the small bowel: a rare association with AL amyloidosis. Am J Surg Pathol 2007; 31:141.</a></li><li><a class="nounderline abstract_t">Brandt K, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med 1968; 44:955.</a></li><li><a class="nounderline abstract_t">Levy DJ, Franklin GO, Rosenthal WS. Gastrointestinal bleeding and amyloidosis. Am J Gastroenterol 1982; 77:422.</a></li><li><a class="nounderline abstract_t">Chang HS, Myung SJ, Yang SK, et al. Massive small bowel bleeding in a patient with amyloidosis. Gastrointest Endosc 2004; 59:126.</a></li><li><a class="nounderline abstract_t">James DG, Zuckerman GR, Sayuk GS, et al. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol 2007; 5:582.</a></li><li><a class="nounderline abstract_t">Yumoto S, Doi K, Higashi T, et al. Intra-abdominal bleeding caused by amyloid transthyretin amyloidosis in the gastrointestinal tract: a case report. Clin J Gastroenterol 2022; 15:140.</a></li><li><a class="nounderline abstract_t">Maher ER, Dutoit SH, Baillod RA, et al. Gastrointestinal complications of dialysis related amyloidosis. BMJ 1988; 297:265.</a></li><li><a class="nounderline abstract_t">Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001; 111:535.</a></li><li><a class="nounderline abstract_t">Madsen LG, Gimsing P, Schiødt FV. Primary (AL) amyloidosis with gastrointestinal involvement. Scand J Gastroenterol 2009; 44:708.</a></li><li><a class="nounderline abstract_t">Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol 1997; 32:78.</a></li><li><a class="nounderline abstract_t">Guirl MJ, Högenauer C, Santa Ana CA, et al. Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol 2003; 98:2219.</a></li><li><a class="nounderline abstract_t">Wixner J, Törnblom H, Karling P, et al. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis. Neurogastroenterol Motil 2018; 30:e13354.</a></li><li><a class="nounderline abstract_t">Yoshiki Y, Yamamoto G, Takazawa Y, et al. AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis. Ann Hematol 2012; 91:467.</a></li><li><a class="nounderline abstract_t">Jones J, VanRosendaal G, Cleary C, et al. Primary amyloidosis presenting as small bowel encapsulation. Can J Gastroenterol 2004; 18:169.</a></li><li><a class="nounderline abstract_t">Willson TD, Bird J, Azizi R, et al. Extraluminal amyloidoma of the pelvic cavity causing large bowel obstruction. Case Rep Gastroenterol 2011; 5:315.</a></li><li><a class="nounderline abstract_t">Shaulov A, Avivi I, Cohen Y, et al. Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature. Amyloid 2018; 25:11.</a></li><li><a class="nounderline abstract_t">Raghunathan V, Louis D, Wirk B. Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis. J Clin Med Res 2017; 9:654.</a></li><li><a class="nounderline abstract_t">Syed U, Ching Companioni RA, Alkhawam H, Walfish A. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management. Eur J Gastroenterol Hepatol 2016; 28:1109.</a></li><li><a class="nounderline abstract_t">Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85:73.</a></li><li><a class="nounderline abstract_t">Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54:271.</a></li><li><a class="nounderline abstract_t">Park MA, Mueller PS, Kyle RA, et al. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82:291.</a></li><li><a class="nounderline abstract_t">Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 1991; 22:904.</a></li><li><a class="nounderline abstract_t">Chopra S, Rubinow A, Koff RS, Cohen AS. Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms. Am J Pathol 1984; 115:186.</a></li><li><a class="nounderline abstract_t">Looi LM, Sumithran E. Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis. Hum Pathol 1988; 19:732.</a></li><li><a class="nounderline abstract_t">Stofer F, Barretto MF, Gouvea AL, et al. A Rare Case of Ascites due to Peritoneal Amyloidosis. Am J Case Rep 2016; 17:439.</a></li><li><a class="nounderline abstract_t">Kim SH, Han JK, Lee KH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003; 58:610.</a></li><li><a class="nounderline abstract_t">Iida T, Yamashita K, Nakase H. Localized Gastrointestinal ALλ Amyloidosis. Clin Gastroenterol Hepatol 2018; 16:e93.</a></li><li><a class="nounderline abstract_t">Araoz PA, Batts KP, MacCarty RL. Amyloidosis of the alimentary canal: radiologic-pathologic correlation of CT findings. Abdom Imaging 2000; 25:38.</a></li><li><a class="nounderline abstract_t">Wang Z, Huang C, Ji F. Primary amyloidosis mimicking Crohn's disease: a case report. Int J Clin Exp Med 2015; 8:16137.</a></li><li><a class="nounderline abstract_t">Bighi S, Trevisani L, Lupi L, et al. Amyloidosis of the gastric stump: radiographic and CT findings. Gastrointest Radiol 1990; 15:197.</a></li><li><a class="nounderline abstract_t">Kahi CJ, Vakili S, Liepnieks JJ, Benson M. Amyloidoma of the esophagus. Am J Gastroenterol 2007; 102:910.</a></li><li><a class="nounderline abstract_t">Saindane AM, Losada M, Macari M. Focal amyloidoma of the small bowel mimicking adenocarcinoma on CT. AJR Am J Roentgenol 2005; 185:1187.</a></li><li><a class="nounderline abstract_t">Peny MO, Debongnie JC, Haot J, Van Gossum A. Localized amyloid tumor in small bowel. Dig Dis Sci 2000; 45:1850.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views. J Gastroenterol Hepatol 2018; 33:583.</a></li><li><a class="nounderline abstract_t">Said SM, Grogg KL, Smyrk TC. Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution. Hum Pathol 2015; 46:491.</a></li><li><a class="nounderline abstract_t">Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 2005; 12:48.</a></li><li><a class="nounderline abstract_t">Shin JK, Jung YH, Bae MN, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis. Mod Rheumatol 2013; 23:406.</a></li><li><a class="nounderline abstract_t">Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54:2997.</a></li><li><a class="nounderline abstract_t">Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009; 28:1113.</a></li><li><a class="nounderline abstract_t">Dainaka K, Isozaki Y, Kunieda K, et al. [A case of gastrointestinal amyloidosis and hypoproteinemia improved by tocilizumab]. Nihon Shokakibyo Gakkai Zasshi 2016; 113:245.</a></li><li><a class="nounderline abstract_t">Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010; 29:1195.</a></li><li><a class="nounderline abstract_t">Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int 2008; 28:1155.</a></li><li><a class="nounderline abstract_t">Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis 2014; 9:61.</a></li><li><a class="nounderline abstract_t">Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997; 27:351.</a></li><li><a class="nounderline abstract_t">Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25:465.</a></li><li><a class="nounderline abstract_t">Gertz MA, Lacy MQ, Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19:136.</a></li><li><a class="nounderline abstract_t">Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60:933.</a></li><li><a class="nounderline abstract_t">Mejhert M, Hast R, Sandstedt B, Janczewska I. Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27:823.</a></li><li><a class="nounderline abstract_t">Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48:2019.</a></li><li><a class="nounderline abstract_t">Levy M, Fryd CH, Eliakim M. Intrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literature. Gastroenterology 1971; 61:234.</a></li><li><a class="nounderline abstract_t">Vaxman I, Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematol 2019; 141:93.</a></li></ol></div><div id="topicVersionRevision">Topic 2642 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22885776" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Colonic amyloidosis, computational analysis of the major amyloidogenic species, Serum Amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6154243" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27536687" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Prevalence and Management of Systemic Amyloidosis in Western Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26161016" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28978215" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733017" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915034" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7863383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8331978" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14464647" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557950" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630180" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822203" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311879" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163134" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/221808" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gastrointestinal-motility dysfunction in amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996842" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastrointestinal motility disturbances in patients with orthostatic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996842" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gastrointestinal motility disturbances in patients with orthostatic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8244111" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259424" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gastrointestinal amyloidosis: radiologic features by chemical types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076735" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gastrointestinal manifestations of amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363891" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18926934" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recurrent obscure gastrointestinal bleeding in a patient with gastric amyloid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797964" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750713" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intermittent subobstruction and cholestasis as complications of duodenal amyloid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197930" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Globular amyloid deposits isolated to the small bowel: a rare association with AL amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4872136" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A clinical analysis of the course and prognosis of forty-two patients with amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979925" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastrointestinal bleeding and amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722567" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Massive small bowel bleeding in a patient with amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428737" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34797488" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intra-abdominal bleeding caused by amyloid transthyretin amyloidosis in the gastrointestinal tract: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3416145" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gastrointestinal complications of dialysis related amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705429" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Primary systemic amyloidosis: a cause of malabsorption syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242859" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary (AL) amyloidosis with gastrointestinal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058299" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572571" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655299" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21643678" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054490" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Primary amyloidosis presenting as small bowel encapsulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21712946" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extraluminal amyloidoma of the pelvic cavity causing large bowel obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241368" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28611868" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27362550" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3389383" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1152671" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Amyloidosis: review of 236 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530778" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1916751" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hepatic amyloidosis: morphologic differences between systemic AL and AA types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6202147" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454214" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27353538" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Rare Case of Ascites due to Peritoneal Amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887954" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Abdominal amyloidosis: spectrum of radiological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29627428" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Localized Gastrointestinal ALλAmyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10652919" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Amyloidosis of the alimentary canal: radiologic-pathologic correlation of CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26629126" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Primary amyloidosis mimicking Crohn's disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2340992" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Amyloidosis of the gastric stump: radiographic and CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397420" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Amyloidoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247131" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Focal amyloidoma of the small bowel mimicking adenocarcinoma on CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052330" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Localized amyloid tumor in small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052330" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Localized amyloid tumor in small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940821" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25649008" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076611" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22815005" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16947531" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19437089" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26853984" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : [A case of gastrointestinal amyloidosis and hypoproteinemia improved by tocilizumab].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20229259" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496698" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767411" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402333" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713619" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272986" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Transplantation for amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7491696" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688930" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014566" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847696" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5314952" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30650422" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
